Oncology and Hematology

PRA is a proven leader in oncology clinical development. We have been instrumental in the successful approvals of major life-extending cancer drugs such as:

• Sutent^®
• Nexavar^®
• Avastin^®
• Tarceva^®
• Velcade^®

PRA provided development and research services that helped to accelerate these products to market. As a leader in oncology, PRA has significant experience in many indications, with considerable expertise in Non-Small Cell Lung Cancer (NSCLC), colorectal cancer and breast cancer. Since 2003, PRA has conducted more than 170 oncology studies and close to 80 hematology studies. In addition, PRA has conducted nearly 100 oncology/hematology consulting projects.

Our strategic alliances with IntrinsiQ and the Geriatric Oncology Consortium expand PRA's ability to:

• Conduct accurate feasibility
• Accrue oncology patients
• Achieve faster study start-ups
• Potentially accelerate the development life cycle

IntrinsiQ

PRA has exclusive access to the powerful patient treatment database of IntrinsiQ Research. This database covers drug therapy administrations to more than 100,000 oncology patients by over 600 oncologists in the US. It provides longitudinal chemotherapy records for more than 45,000 cancer treatments per month that are based on actual treatment data. For an IntelliView example on a colorectal cancer treatment flow, please click here.

Phase I – Phase IV Clinical Trial Experience

PRA has conducted close to 100 oncology/hematology consulting projects covering all aspects of clinical development from feasibility to translational medicine and post-marketing analysis and reporting.

Close to 85,000 subjects were participating in these oncology and hematology trials.